· Vision and Mission
Qizheng Tibetan Medicine achieved a net profit of 319 million yuan in 2018 and plans to distribute 4.1 yuan for every 10 shares held, along with a bonus of 3 shares per 10 shares held.
Release time:
2019-04-18 15:45
On the evening of April 18, Qizheng Tibetan Medicine (002287) released its 2018 annual report. In 2018, the company achieved operating revenue of 1.213 billion yuan, an increase of 15.2% year-on-year; net profit attributable to shareholders of the listed company reached 319 million yuan, up 5.96% year-on-year; and basic earnings per share amounted to 0.79 yuan. The company proposes to distribute a cash dividend of 4.1 yuan (including tax) for every 10 shares held by all shareholders, along with a bonus share issue of 3 shares (including tax).
The annual report shows that, as of the end of 2018, one product had been included in the National Essential Medicines List, 17 products were listed in the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2017 Edition)," 53 products had been included in local provincial medical insurance lists, 26 products had been included in local essential medicine lists, 41 products had been included in the urban and rural resident medical insurance or New Rural Cooperative Medical Scheme lists, 9 products had been included in local low-price drug lists, and 2 products had been included in the National Emergency (Rescue) Drug List.
The company stated that in 2019, it will continue to strengthen academic leadership and professional-driven initiatives to ensure the sustainable development of its business. With a focus on bolstering its core pain management product line—centered around pain-relief patches—and in collaboration with Bai Mai Ointment, Qing Peng Ointment, and Ruyi Zhenbao Tablets, the company will build an integrated brand and academic marketing strategy for pain management, while exploring digital marketing models for prescription drugs. The company will also emphasize urban expansion, deepening distribution channels, and building grassroots academic marketing platforms, aiming to establish benchmark hospitals in terms of academic excellence. Furthermore, the company will expand its product offerings in the fields of women’s and children’s healthcare, promote the “Shan Wei” family of gastrointestinal products and the “Hu Fei” family of respiratory products, and integrate Tibetan medicine’s distinctive treatment protocols for key disease areas. This comprehensive approach will provide customers with holistic diagnostic and therapeutic solutions, driving the joint growth of all the company’s product lines.
Later that evening, the company released its first-quarter report for 2019. From January to March 2019, the company achieved operating revenue of 254 million yuan, an increase of 11.78% year-on-year; net profit attributable to shareholders of the listed company reached 84.7755 million yuan, up 9.98% year-on-year; and basic earnings per share amounted to 0.21 yuan.
Reporting media: China Securities Journal
Report link: http://www.cs.com.cn/ssgs/gsxw/201904/t20190418_5940651.html
Copyright Qizheng Tibetan Medicine Co., Ltd. All rights reserved. ICP Filing Number:
Internet drug information service qualification certificate number:（藏） Non-Commercial - 2018-0004 SEO